0001209191-19-000270.txt : 20190102
0001209191-19-000270.hdr.sgml : 20190102
20190102162022
ACCESSION NUMBER: 0001209191-19-000270
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181231
FILED AS OF DATE: 20190102
DATE AS OF CHANGE: 20190102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MARLETT CHRISTOPHER A
CENTRAL INDEX KEY: 0000897744
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38327
FILM NUMBER: 19501918
MAIL ADDRESS:
STREET 1: 100 WILSHIRE BLVD
CITY: SANTA MONICA
STATE: CA
ZIP: 90401
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cue Biopharma, Inc.
CENTRAL INDEX KEY: 0001645460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473324577
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 W. KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-949-2680
MAIL ADDRESS:
STREET 1: 675 W. KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Imagen Biopharma, Inc.
DATE OF NAME CHANGE: 20150617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-12-31
0
0001645460
Cue Biopharma, Inc.
CUE
0000897744
MARLETT CHRISTOPHER A
2425 CEDAR SPRINGS ROAD
DALLAS
TX
75201
1
0
0
0
Common Stock
2018-12-31
4
P
0
18521
4.64
A
89602
I
See footnote
Common Stock
9000
D
Common Stock
1017973
I
See footnote
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.56 to $4.70, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee.
The record owner of these securities is MDB Capital Group, LLC ("MDB"). The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of Section 16 or any other purposes.
/s/ Christopher Marlett by Mark R. Busch, attorney-in-fact
2019-01-02